News

Knowridge Science Report21h
Single-dose RSV vaccine protects older adults across three seasons, global study finds
A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...
Single-dose vaccine demonstrates sustained efficacy against RSV-related lower respiratory tract disease in older adults
Researchers from GlaxoSmithKline have reported that a single dose of the RSV vaccine, Arexvy (RSVPreF3 OA), provides ...
Zacks Investment Research on MSN4d
GSK & PFE's RSV Vaccines Recommended for Use in Adults Aged 50-59
GSK GSK and Pfizer PFE announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on ...
Fierce Pharma4d
RSV shots from GSK, Pfizer get potential boost from broadened ACIP guidance
A year after narrowing its recommendation for who should use vaccines to defend against respiratory syncytial virus (RSV), a ...
US Advisory Panel Votes To Expand Recommendation For Pfizer, GSK's RSV Vaccines For Older Adults Below 60 Years
On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...
pharmaphorum4d
There's good news for RSV jab firms at delayed ACIP meeting
The Advisory Committee on Immunisation Practices (ACIP) has voted to widen the recommendations on the use of RSV shots to ...
Business Wire5d
AREXVY recommended for adults aged 50-59 at increased risk for severe respiratory syncytial virus (RSV) disease by US Advisory Committee on Immunization Practices
About AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) AREXVY contains recombinant RSV glycoprotein F stabilized in the prefusion conformation (RSVPreF3). This antigen is combined with GSK ...
MedPage Today on MSN5d
ACIP Endorses RSV Vaccine for At-Risk Adults 50 and Up
The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...
GSK ‘pleased’ ACIP voted in favor of using RSV vaccines
GSK (GSK) said it is “pleased” that the Advisory Committee on Immunization Practices voted in favor of recommending the use of RSV vaccines ...
Medical Dialogues2d
GSK Arexvy recommended for adults aged 50-59 at increased risk for severe RSV disease by US Advisory Committee on Immunization Practices
GSK plc has announced that the Advisory Committee on Immunization Practices (ACIP) voted in favour of recommending the use of RSV vaccines including GSK’s Arexvy (Respiratory Syncytial ...